Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
Rhea-AI Summary
Oncolytics (Nasdaq: ONCY) scheduled a Type C meeting with the FDA on April 16, 2026 to discuss a potential single-arm registrational pathway for pelareorep in second-line and later squamous cell anal carcinoma (SCAC).
The company intends to propose a pivotal single-arm study enrolling ~60–70 patients with objective response rate (ORR) as the primary endpoint; prior Cohort 4 data showed ~30% ORR and median duration of response of 17 months.
Positive
- Type C meeting with FDA set for April 16, 2026
- Cohort 4 showed approximately 30% ORR and 17-month median duration of response
- Company proposes a single-arm pivotal study enrolling 60–70 patients with ORR primary endpoint
Negative
- SCAC is a rare indication with ~54,000 global annual cases, potentially limiting enrollment
- Proposed single-arm design may rely on historical comparators rather than randomized control
News Market Reaction – ONCY
In the Apr 6 session, ONCY declined 1.07%, reflecting a mild negative market reaction. Argus tracked a trough of -3.9% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | U.S. domestication | Positive | +9.6% | Completed redomestication to Nevada to streamline regulation and access U.S. capital. |
| Mar 19 | AACR data preview | Positive | +1.9% | Reported strong translational data supporting pelareorep as an immune-priming backbone. |
| Mar 02 | CRC Phase 2 launch | Positive | -9.7% | Launched randomized Phase 2 REO 033 in 2L RAS‑mutant MSS metastatic colorectal cancer. |
| Feb 24 | Program prioritization | Positive | +6.6% | Prioritized registration-focused pelareorep programs in SCAC and metastatic colorectal cancer. |
| Feb 04 | Fast Track granted | Positive | +2.5% | FDA granted Fast Track for pelareorep plus bevacizumab and FOLFIRI in 2L KRAS-mutant MSS CRC. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent ONCY news has generally been positive and often followed by gains, though the March 2 colorectal trial launch saw a notable negative divergence despite constructive clinical framing.
Over the past few months, Oncolytics has advanced pelareorep and its corporate structure. In Feb 2026, it received FDA Fast Track for 2L KRAS‑mutant MSS metastatic CRC and later prioritized registration-focused programs in anal and colorectal cancer, expecting a registrational SCAC study with well under 100 subjects. A randomized CRC study and AACR mechanistic data followed. On Apr 1, 2026, the company completed its U.S. domestication to Nevada. Today’s Type C FDA meeting announcement fits this trajectory toward a registrational path in SCAC.
Key Terms
single-arm pivotal study technical
checkpoint inhibitor medical
squamous cell anal carcinoma medical
objective response rate medical
median duration of response medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration (“FDA”) on April 16, 2026, to discuss a potential registrational development path in anal cancer.
The meeting will focus on the potential to initiate a single-arm pivotal study evaluating pelareorep in combination with a checkpoint inhibitor in patients being treated with second-line and later therapy for squamous cell anal carcinoma (“SCAC”). Patients will have received a checkpoint inhibitor and chemotherapy in the first-line, which means all patients treated in this study would have no alternative approved therapies available at this stage of treatment. The Company intends to discuss a study design enrolling approximately 60 to 70 patients with objective response rate (“ORR”) as the primary endpoint to support a potential full approval.
Pelareorep, in combination with a checkpoint inhibitor, has demonstrated encouraging clinical activity in SCAC. In Cohort 4 of the GOBLET study, the combination achieved approximately
“We believe this upcoming FDA meeting is a critical step in advancing pelareorep toward a potential registration pathway in anal cancer,” said Jared Kelly, Chief Executive Officer of Oncolytics. “Our goal is to align with the FDA on the statistical analysis plan and sample size for a potential pivotal single-arm study in second-line and later SCAC. In a setting with limited approved therapies, we believe the strength and durability of our data support this approach, and recent regulatory discussions in oncolytic virus development underscore the importance of demonstrating clear, durable clinical benefit with checkpoint inhibition. With few late-line options and no confounding checkpoint inhibitor data, SCAC offers a clearer efficacy signal and a potentially more efficient path to approval for pelareorep.”
SCAC is a rare cancer with limited treatment options in the second-line and later setting, and outcomes remain poor following progression on first-line treatment. The World Health Organization estimates that there are approximately 54,000 cases of anal cancer globally each year, and the anal cancer market is expected to double to
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer, and early-phase studies in anal and colorectal cancer. It is designed to induce anti-cancer immune responses by converting immunologically “cold” tumors “hot” through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers, where pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the Company on social media on LinkedIn and on X @oncolytics.
Forward-looking statements
This press release contains forward-looking statements, within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements contained in this press release include statements regarding beliefs as to the potential, registration, mechanism of action and benefits of pelareorep as a cancer therapeutic; the Company’s goals, strategies, and objectives; expectations around the design, milestones, anticipated timelines and expected outcomes for current and future studies; its belief in the clinical promise of pelareorep in anal, colorectal, pancreatic and other gastrointestinal cancers; and the Company’s goals and expectations for its upcoming FDA meeting on a potential registrational development path for pelareorep in anal cancer. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, access to capital markets, and market dynamics. Please refer to Oncolytics’ public filings with securities regulators in the United States and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law.
References
- Rao S, et al. Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy. Annals of Oncology. 2020 September. doi: https://doi.org/10.1016/j.annonc.2020.08.2272.
- International Agency for Research on Cancer. (2020). Anus fact sheet. Global Cancer Observatory. World Health Organization. https://gco.iarc.who.int/media/globocan/factsheets/cancers/10-anus-fact-sheet.pdf.
- Market Research Future. (n.d.). Anal cancer market research report – Forecast to 2030. https://www.marketresearchfuture.com/reports/anal-cancer-market-1530.
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
